TB is caused by bacteria (Mycobacterium tuberculosis) that often affect the lungs.
Professor Andrew Owen, from the University of Liverpool's department of molecular and clinical pharmacology, is part of an international research team that will explore why some patients respond positively to anti-TB drug treatment while in other patients the treatments fail or the patients experience toxicity. In patients with HIV / AIDS the percentage of patients that are not cured by therapy is even higher.
TB is the second leading cause of death from an infectious disease worldwide after HIV / AIDS. In 2010 there were 8.8 million new cases of TB and 1.1 million deaths, including 350,000 deaths from TB among people with HIV. In Sub-Saharan Africa TB poses a major public health problem and is the leading killer of people living with HIV, causing one quarter of all deaths.
Professor Owen says, ''There is a much greater understanding of genes which affect how we react and respond to drugs used in other diseases such as HIV than there is for TB. This project will study the genes of patients being treated with the four main anti-TB drugs, and also with a new drug which is in development, using clinical trial sites in Benin, Senegal and South Africa.
''There is a much greater understanding of genes which affect how we react and respond to drugs used in other diseases such as HIV than there is for TB''
''The study aims to explore and determine genetic differences which affect the effectiveness and reaction to anti-TB drugs. It is funded through the H3Africa project, which is led by African scientists and one of its aims is to foster capacity-building for research in Sub Saharan Africa.''
The standard treatment for TB is a six-month course of four drugs taken daily for two months, followed by two drugs taken for a four-month period but as many as 10 per cent of patients do not respond to this treatment. Patients who have been treated with anti-TB drugs have an increased risk of spreading a strain of TB that is resistant to drug treatments.